Title : The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.

Pub. Date : 2014 Jun 1

PMID : 24374738






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Gefitinib AKT serine/threonine kinase 1 Homo sapiens
2 The activation of AKT was associated with disease progression in tumors with wild-type EGFR from patients treated with gefitinib (phase II clinical trial IFCT0401). Gefitinib AKT serine/threonine kinase 1 Homo sapiens
3 The PI3K/AKT pathway is thus a major pathway contributing to gefitinib resistance in lung tumors with KRAS mutation, through the regulation of the BAX/Ku70 interaction. Gefitinib AKT serine/threonine kinase 1 Homo sapiens